Fund moves

Dexcom (DXCM): Voleon Capital Management LP added to its stake +185K shares

Voleon Capital Management LP added to its stake in Dexcom, per its Q3 2025 13F.

252K
Shares reported · +185K vs prior quarter
0.41%
Disclosed portfolio weight
$17M
Reported value
Holdings as of
Sep 30, 2025
Filed
Nov 14, 2025

What stands out in this filing

  • 67,809 shares in Q2 2025, 252,318 now (+272.1% in share count).
  • Reported at $17M, 0.41% of the portfolio value in this 13F filing.
  • 32 other tracked managers reported the same kind of change for Q3 2025.

Calculated by OQRO from this filing and the public records it holds. Facts about the record, not a reason for the trade and not a signal.

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Sep 14, 2025Company filing · Form 8-K · Executive changeChanged a top executive or board member“Effective September 14, 2025, Kevin R. Sayer, Chief Executive Officer (principal executive officer) and Chairman of the Board of DexCom, Inc. (“Dexcom” or the “Company”) is taking a temporary medical leave of absence.”
  2. Oct 24, 2025Company filing · Form 8-K · Executive change, Reg FDChanged a top executive or board member, and shared information with investors“On October 24, 2025, the Board of Directors (the “Board”) of DexCom, Inc. (“Dexcom” or the “Company”), pursuant to the Amended and Restated Bylaws of the Company, increased the size of the Board to ten directors and appointed Dr. Euan Ashley as a director, effective immediately.”
  3. Oct 27, 2025Court · District Court, S.D. New YorkSecurities lawsuit filed: Prime v. DexCom, Inc.
  4. Oct 30, 2025Company filing · Form 8-K · ResultsReported its results
  5. Oct 30, 20255% stakeThe Vanguard Group reported a passive stake (13G) of 12.6%
  6. Nov 10, 2025Court · District Court, S.D. New YorkSecurities lawsuit filed: Oakland County Employees Retirement System v. DexCom, Inc.
  7. Nov 10, 2025Insider · 2 peopleInsiders: 2 purchases (~$1.0M), 1 sale (~$218K)
  8. Nov 12, 2025InsiderDirector sold ~$59K of DXCM shares in the open market
  9. Nov 14, 2025InsiderDirector sold ~$172K of DXCM shares in the open market

What came next

  1. Nov 18, 2025FDAFDA device clearance: Dexcom Smart Basal
  2. Nov 25, 2025Court · District Court, S.D. CaliforniaSecurities lawsuit filed: Boston Retirement System v. Dexcom, Inc.
  3. Dec 17, 2025FDAFDA device clearance: Dexcom G7 Continuous Glucose Monitoring (CGM) System, Dexcom G7 15 Day Continuous Glucose Monitoring (CGM) System
  4. Dec 19, 2025Company filing · Form 8-K · Executive changeChanged a top executive or board member“As previously reported on the Current Report on Form 8-K filed on July 30, 2025, the Board of Directors (the “Board”) of DexCom, Inc. (“Dexcom” or the “Company”) appointed Jacob S. Leach, President and Chief Operating Officer, as the President and Chief Executive Officer and as a director of the Company, effective January 1, 2026, following Kevin R. Sayer’s resignation, effective as of such date.”
  5. Jan 7, 2026Company filing · Form 8-K · ResultsReported its results
  6. Jan 26, 2026CongressDisclosed purchase of DXCM — reported range $1,001 - $15,000
  7. Feb 3, 2026FDAFDA device clearance: Dexcom G7 Continuous Glucose Monitoring (CGM) System; Dexcom G7 15 Day Continuous Glucose Monitoring (CGM) System
  8. Feb 12, 2026Company filing · Form 8-K · ResultsReported its results
  9. Feb 12, 2026InsiderDirector sold ~$69K of DXCM shares in the open market
  10. Feb 26, 2026Company filing · Form 8-K · Executive change, Reg FDChanged a top executive or board member, and shared information with investors“On February 26, 2026, the Board of Directors (the “Board”) of DexCom, Inc. (“Dexcom” or the “Company”), pursuant to the Amended and Restated Bylaws of the Company, increased the size of the Board to twelve directors and appointed Albert F. (“Rick”) Osterloh, IV as a director effective immediately.”
  11. Feb 27, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“As previously reported on the Current Report on Form 8-K filed on July 30, 2025, Kevin R. Sayer notified the Board of Directors (the “Board”) of DexCom, Inc. (“Dexcom” or the “Company”) of his intent to retire from his role as Chief Executive Officer effective January 1, 2026.”
View the official recordSEC Form 13F-HR

How to read SEC Form 13F-HR

Form 13F is the quarterly report in which investment managers that oversee $100 million or more list the US-listed stocks and some other securities they held on the last day of the quarter.

Full guide: What is an SEC Form 13F?

What else is on file for Dexcom

For Dexcom, OQRO holds 20 insider filings (SEC Form 4 or Form 144) and 1 fund holdings report (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its DXCM page.

How this filing works

Explore the data

Common questions

What does this filing report about Dexcom (DXCM) stock?

Voleon Capital Management LP added to its stake in Dexcom, per its Q3 2025 13F. Now 252K shares, $17M reported value, 0.41% of disclosed portfolio.

When did it happen, and when was it made public?

Holdings as of: Sep 30, 2025. Filed: Nov 14, 2025.

What stands out in this filing?

67,809 shares in Q2 2025, 252,318 now (+272.1% in share count). Reported at $17M, 0.41% of the portfolio value in this 13F filing. 32 other tracked managers reported the same kind of change for Q3 2025.

Is this a trade made on a known date?

No. A holdings report is a picture of the portfolio on the last day of the quarter. It shows what was held on that day, not the day or the price at which anything was bought or sold.

Where does this information come from?

From the SEC Form 13F-HR, a public record. The link to the official record is on this page, and OQRO copies its figures without changing them.

What else has been disclosed about Dexcom recently?

For Dexcom, OQRO holds 20 insider filings (SEC Form 4 or Form 144) and 1 fund holdings report (13F) dated in the last 90 days. They are listed on the DXCM page.

Does this mean DXCM stock is a buy or a sell?

No. This page describes one public filing. A filing does not say why someone traded and is not a forecast, so OQRO gives no recommendation.

Is OQRO free?

Yes. Every page of OQRO is free with an account, which takes a minute with Google and needs no card. Only the AI assistant is paid.

Other disclosures at Dexcom

Everything OQRO holds on this company is on its DXCM page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

OQRO is free for everyone. No card, no trial

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data